tradingkey.logo

HUTCHMED (China) Ltd

HCM
查看詳細走勢圖
13.550USD
+0.200+1.50%
收盤 12/19, 16:00美東報價延遲15分鐘
11.82B總市值
25.06本益比TTM

HUTCHMED (China) Ltd

13.550
+0.200+1.50%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.50%

5天

+0.97%

1月

-4.44%

6月

-8.69%

今年開始到現在

-5.97%

1年

-5.31%

查看詳細走勢圖

TradingKey HUTCHMED (China) Ltd股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值低估,機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間,可以做區間波段操作。

HUTCHMED (China) Ltd評分

相關信息

行業排名
135 / 173
全市場排名
552 / 4682
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 12 分析師
買入
評級
21.215
目標均價
+51.10%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

HUTCHMED (China) Ltd亮點

亮點風險
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
業績高增長
公司營業收入穩步增長,連續3年增長47.79%
估值低估
公司最新PE估值27.48,處於3年歷史低位
機構減倉
最新機構持股6.34M股,環比減少47.27%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉1.17K股

HUTCHMED (China) Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

HUTCHMED (China) Ltd簡介

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
公司代碼HCM
公司HUTCHMED (China) Ltd
CEOCheng (Chig Fung)
網址https://www.hutch-med.com/

常見問題

HUTCHMED (China) Ltd(HCM)的當前股價是多少?

HUTCHMED (China) Ltd(HCM)的當前股價是 13.550。

HUTCHMED (China) Ltd 的股票代碼是什麼?

HUTCHMED (China) Ltd的股票代碼是HCM。

HUTCHMED (China) Ltd股票的52週最高點是多少?

HUTCHMED (China) Ltd股票的52週最高點是19.500。

HUTCHMED (China) Ltd股票的52週最低點是多少?

HUTCHMED (China) Ltd股票的52週最低點是11.505。

HUTCHMED (China) Ltd的市值是多少?

HUTCHMED (China) Ltd的市值是11.82B。

HUTCHMED (China) Ltd的淨利潤是多少?

HUTCHMED (China) Ltd的淨利潤為37.73M。

現在HUTCHMED (China) Ltd(HCM)的股票是買入、持有還是賣出?

根據分析師評級,HUTCHMED (China) Ltd(HCM)的總體評級為買入,目標價格為21.215。

HUTCHMED (China) Ltd(HCM)股票的每股收益(EPS TTM)是多少

HUTCHMED (China) Ltd(HCM)股票的每股收益(EPS TTM)是0.541。
KeyAI